T he heart derives most of its energy via mitochondrial oxidative metabolism. The heart's fuels or energy substrates include fatty acids, lactate, glucose, and ketones. Substrate concentrations vary during the day, driven mainly by postprandial status. Entry into mitochondrial oxidation requires metabolism to acetyl-coenzyme A (CoA), the fuel of the tricarboxylic acid (TCA) cycle. Acetyl-CoA oxidation generates reduced Nicotinamide adenine dinucleotide (NADH), which drives oxidative phosphorylation, the reduction of O 2 to H 2 O, and, ultimately, the synthesis of ATP, which is essential for myocardial mechanics. The heart uses this highly regulated series of enzyme-catalyzed reactions to convert chemical energy into mechanical energy. 1 Metabolism and function in the heart are inextricably linked.
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MRS Measures of Metabolism
The pathological states of the heart, such as ischemia, hypertrophy, and failure, modify metabolism. Available technologies to measure intermediary metabolism have been inadequate. Magnetic resonance spectroscopy (MRS) can be used to spatially map or at least locally measure metabolism in vivo. Measurement of endogenous triglycerides in patients using 1 H MRS has demonstrated that cardiac steatosis precedes the onset of type 2 diabetes mellitus and left ventricular systolic dysfunction. 2 In the failing human heart and in preclinical heart failure models, 31 P MRS has shown that flux through the creatinine kinase reaction is altered. 3, 4 Also, ATP and phosphocreatine are reduced after myocardial infarction due to myocyte loss. 5 Myocardial energy substrate can be measured with 13 C MRS. It has the chemical specificity, but its inherently low sensitivity limits the spatial and temporal resolution necessary for clinical application. In isolated hearts, 13 C MRS has to be used with labeled substrate molecules to define TCA cycle kinetics. The metabolites of the TCA cycle have not been measured directly in these experiments. The content of the TCA cycle metabolites is too low to be observed using equilibrium magnetization 13 C spectroscopy, but 13 C glutamate, which is derived from TCA metabolites, can be measured and used in kinetic analysis. In cardiac hypertrophy, fatty acid oxidation rates are reduced, and compensatory increases in anaplerosis to maintain TCA cycle flux have been observed. 6 This shift away from acetyl-CoA production toward carbon influx via anaplerosis bypasses energy, yielding reactions contributing to a less energy-efficient metabolism.
Magnetic resonance is inherently an insensitive technique. The MR signal arises from a difference in the population of nuclear spins aligned or against the magnetic field. The difference in population is field and temperature dependent, but it is small (Ϸ1 nucleus in 100 000 for 1 H and lower for other nuclei). The small difference in populations or polarization is responsible for the insensitivity of MR. This does not adversely affect 1 H MR imaging because of the relative abundance of water ( 1 H 2 O Ϸ80 mol/L protons), but it severely affects other nuclei, which are typically present in molecules with concentrations in the millimolar range. One way to overcome this low sensitivity is to increase the magnetic field strength. The gain in MR signal is at least linear with field strength, as observed in studies using 3-and 7-T magnets, now available for human studies. Although the use of a higher magnetic field is not always advantageous for 1 H MR imaging, it facilitates MRS of most other nuclei.
Methods to increase MR signal have been developed. Several different techniques, which are termed hyperpolarization, are feasible, but the most prevalent technique for hyperpolarizing nuclei is low-temperature dynamic nuclear polarization (DNP). 7 The DNP process works by mixing the molecule to be hyperpolarized with a source of free electrons, typically a trityl radical. This mixture is cooled to low temperatures (Ϸ1.2 K) in a high-magnetic field, which ensures that the electrons in the trityl radical are Ϸ100% polarized. Microwave irradiation of an electron-spin resonance line transfers polarization from the electrons in the free radical to nearby nuclei in the molecule of interest, which contains a nucleus that is enriched with 13 C (or any suitable MR-active nucleus). After steady-state polarization is achieved, the sample is rapidly melted and ejected from the magnet. This solution is ready for measurement in cells, tissues, or animals. The initial DNP-polarized signal is Ϸ10 000 times that of the same sample, polarized in a high-magnetic field at 298 K. This gain in signal allows the rapid detection (Ϸ1 second) by 13 C MRS of nuclei in the polarized molecule or its metabolites, if those nuclei have different chemical shifts (frequencies). Hyperpolarized 13 C molecules can provide sufficient MR signal to spatially encode the signals and create spectroscopic images of metabolic activity. 8 A limitation of the method is that the hyperpolarized signal begins to decay toward its equilibrium value, which is temperature and magnetic field dependent, immediately on melting. This relaxation process is characterized by the longitudinal relaxation rate constant (T 1 ) for the nucleus. The total time available for measurement (melting, delivery to animal, injection, time to target tissue, and rate of metabolism) is variable, but the exponential relaxation process will dissipate the polarization in 5 to 7 times the value of the T 1 . The MRS sampling measurement also reduces the signal polarization, further limiting the time available for signal measurement. These time constraints limit the reactions that can be interrogated with hyperpolarized 13 C MRS.
Most studies using 13 C hyperpolarized molecules have used 1-13 C pyruvate (C1 is the carboxyl group). This molecule has several favorable features. Because the C1 resonance is not protonated (no directly bonded protons), its T 1 is Ϸ30 seconds. This allows Ϸ200 seconds available for the entire dissolution to measurement process. It is also rapidly transported and metabolized into 1-13 C lactate and H 13 CO 3 -( 13 CO 2 ). The chemical shift range of 1-13 C pyruvate and its metabolites is sufficient to allow detection of all three species.
Hyperpolarized 13 C MRS and Metabolism
The metabolism of hyperpolarized 1-13 C pyruvate has recently been measured in the perfused rat heart 9 and the in vivo rat heart. 10 Dissolved 13 CO 2, the product of pyruvate dehydrogenase (PDH) activity, and H 13 CO 3 -, bicarbonate, the hydrated form of 13 CO 2 , were observed with a 1-second resolution. The rate of 13 CO 2 and H 13 CO 3 production from 1-13 C pyruvate reflected flux through PDH. Spectroscopic imaging of the intact rat has followed the metabolism of hyperpolarized 1-13 C pyruvate into 1-13 C lactate and H 13 CO 3 in liver, kidney, and skeletal muscle. 11 2-13 C pyruvate (C2 is the keto carbon) has also been hyperpolarized with DNP. 9 The keto carbon 13 C label enters the TCA cycle.
Acetyl-CoA, Carnitine, and Intermediary Metabolism
The 2 major pathways that generate acetyl-CoA are the ␤-oxidation of fatty acids and the decarboxylation of pyruvate by PDH. Fatty acids are derived from the blood or lipolysis of endogenous triglycerides. Circulating pyruvate is low (Ͻ100 mol/L); therefore, intracellular pyruvate is derived from lactate and from glucose via glycolysis. There are 2 checkpoints for the entry of pyruvate and fatty acids into oxidative metabolism. For pyruvate, it is the activity of PDH. The PDH activity is regulated by the balance between phosphorylation by PDH kinase and dephosphorylation by PDH phosphatase. PDH kinase activity is modulated by the intramitochondrial acetyl-CoA/CoA-SH and the NADH/ NAD ratios. An increase in the acetyl-CoA/CoA-SH ratio activates PDH kinase, resulting in increased phosphorylation of PDH, which results in an inhibition of PDH activity.
For fatty acids, the major control point is on the outer mitochondrial membrane, where long-chain fatty acyl-CoA must be converted to acyl-carnitine, the acyl being the fatty acid, by carnitine-palmitoyl transferase I (CPTI). The CPTI activity is regulated by malonyl-CoA. Acyl-carnitines are translocated through the mitochondrial inner membrane via a translocase. In the mitochondrion, CPTII transfers the acylgroup from acyl-carnitine to acyl-CoA, reforming acyl-CoA, which enters ␤-oxidation. This acylcarnitine shuttle system maintains distinct fatty acyl-CoA pools in the cytosol and mitochondria.
In addition to the long-chain acyl-CPT, there is another carnitine acyl transferase, 12 which is carnitine acetyl transferase (CAT). The CAT activity in the heart is high. The CAT reaction is as follows:
Acetyl-CoAϩCarnitine7Acetyl-CarnitineϩCoA-SH (1) The reaction appears to be at equilibrium. The CAT is the only enzyme that transforms acetyl-carnitine. Once formed in the mitochondria, acetylcarnitine can be translocated into the cytosol. 12 There is low CAT activity present in the heart cytosol. 13 Thus, little, if any, acetylcarnitine will be converted into acetyl-CoA outside of the mitochondria. In 1967, Pearson and Tubbs 14 proposed that acetylcarnitine acts as an acetyl-CoA buffer in the mitochondrion to maintain acetyl-CoA/CoA-SH, much as phosphocreatine does for ATP in the cytosol.
Carnitine alters the acetyl-CoA/CoA-SH ratio, which influences the oxidation of pyruvate and fatty acid. Studies with heart mitochondria have shown that carnitine increases CoA levels and reduces acetyl-CoA levels, resulting in a 10-to 20-fold decrease in the ratio of acetyl-CoA/CoA, which correlated with the efflux of acetylcarnitine from the mitochondria. 15 In isolated nonischemic hearts perfused with glucose as the only fuel, the addition of palmitate, which increases acetyl-CoA/CoA-SH, results in a reduction in glucose oxidation. Adding carnitine to the perfusion restored glucose oxidation and decreased palmitate oxidation. 12 In this issue of Circulation: Cardiovascular Imaging, Schroeder et al 16 use 13 C MRS measurements of hyperpolarized 2-13 C pyruvate, which is transformed to 1-13 C acetyl-CoA by PDH, to dynamically follow the appearance of 13 C label in acetylcarnitine via the CAT reaction in the isolated perfused and in the intact rat heart. By using the powerful MR technique of saturation transfer in the isolated heart, the authors found that saturating or abolishing the 1-13 C acetylcarnitine resonance reduced by Ϸ50% the magnitudes of TCA cycle-derived 1-13 C citrate and 5-13 C glutamate resonances. This demonstrates that about half of the PDH-derived acetyl-CoA cycles into the acetylcarnitine pool before it is reconverted to acetyl-CoA and incorporated into citrate (see Figure 1 in Schroeder). 16 The infusion of dichloroacetate in vivo, which stimulates PDH activity, resulted in a 35% increase in the production 1-13 C acetylcarnitine (and a comparable increase in total acetylcarnitine in extracts) from 2-13 C pyruvate. Although PDH flux increased with dichloroacetate, the rate of 13 C label incorporation into 1-13 C citrate and 5-13 C glutamate (via TCA cycle activity) was unchanged. This demonstrates that CAT activity buffers acetyl-CoA by formation of acetylcarnitine and maintains the acetyl-CoA/ CoA-SH ratio, supporting the hypothesis of Pearson and Tubbs. 14 Myocardial carnitine content decreases in experimental pathological conditions, such as ischemia and hypertrophy. In a metabolomic study 17 of the arterial and venous blood of patients undergoing cardiac surgery, after reperfusion, there was a release of acetylcarnitine from the heart. In patients with dilated cardiomyopathy and congestive heart failure, biopsy measurements found that myocardial carnitine was reduced Ϸ50%; in the plasma of patients with congestive heart failure, carnitine levels were elevated. 18 Carnitine can be supplemented as L-carnitine, acetyl-Lcarnitine, or propionyl L-carnitine. In hypertrophic rat hearts, propionyl L-carnitine, administered by either perfusion in vitro or diet in vivo, increased function and glucose oxidation. 19 Several clinical trials have indicated some beneficial effects to adding carnitine to standard medical therapy for heart failure. The L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico trial was a randomized, double-blind, placebo-controlled, multicenter trial in which 472 patients with a first acute myocardial infarction received either placebo or L-carnitine within 24 hours of onset of chest pain and treatment was continued for 12 months. 20 The increase in both left ventricular end-diastolic and end-systolic volumes, measured by 2D echo, was reduced in the L-carnitine group. In a randomized, single-blind, placebo-controlled trial in 30 patients with heart failure, oral administration of 1.5 g/d of propionyl-L-carnitine for 1 month resulted in significantly improved measures of exercise tolerance and a slight, but significant, decrease in left ventricular size, compared with placebo. 21 The actions of L-carnitine and propionyl-L-carnitine cannot be explained as exclusively dependent on the stimulation of fatty acid oxidation but rather on a marked increase in glucose oxidation, via a relief of PDH inhibition caused by the elevated acetyl-CoA/CoA-SH ratio. 22 The enhanced pyruvate use is thought to be beneficial because less pyruvate is converted to lactate, resulting in intracellular acidification. Potentially hyperpolarized MRS could test the previously described hypothesis for the role of carnitine in vivo: 2-13 C pyruvate could measure the production of 1-13 C acetylcarnitine; 1-13 C pyruvate is rapidly converted to 1-13 C lactate; and H 13 CO 3 can be used to measure intracellular pH. 23 There is, of course, much work necessary to achieve this potential. Even with the gains in signal available with hyperpolarization, MR still requires relatively high levels of labeled substrates. The plasma pyruvate concentration used by Schroeder et al 16 was 250 mol/L, which is 25% higher than baseline in the rat.
Hyperpolarized 13 C MRS has great potential to develop as a new tool to measure metabolism. Evaluation of intermediary metabolism, such as TCA cycle activity, may be useful diagnostically in patients. For example, some drug therapies that influence fatty acid oxidation may be beneficial in the treatment of heart failure. 1 Dichloroacetate, which promotes glucose oxidation over glycolysis, improves survival in several models of rat pulmonary artery hypertension 24 and has been proposed for human trials. These interventions are difficult to study because of the limitations of current tech-nology. Much could be learned with a powerful and versatile in vivo metabolic measurement technique.
Future Directions
Hyperpolarization technology is still in its infancy, and current polarizer equipment and methods are suboptimal. Much remains to be done at the basic level to develop the MR techniques (specialized MR probes, fast spectroscopic imaging pulse sequences, improved data reconstruction, and analysis methods) to detect hyperpolarized 13 C-labeled molecules. There do not appear to be fundamental barriers to the rapid translation of this technology to clinical research and perhaps to clinical care. 25 A more extensive overview of the basis, the use, and the potential clinical applications of hyperpolarized 13 C MRS in the heart may be found in a recent installment of Circulation's Basic Science for Clinicians. 26 
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